Celestene Generic Drug
Therapeutic class: Anti-inflammatories
active ingredients: Betamethasone
laboratory: EG Labo
Oral solution drops
Box of 1 Bottle with 30 ml dropper
AFFECTIONS OR DISEASES :
I - COLLAGENOSES, CONNECTIVITIES :
Evolutionary thrusts of systemic diseases, including: systemic lupus erythematosus, vasculitis, polymyositis, visceral sarcoidosis.
II - DERMATOLOGICAL
a - Severe autoimmune bullous dermatoses, especially pemphigus and bullous pemphigoid.
b - severe forms of the angiomas of the infant.
c - certain forms of lichen plan.
d - certain acute urticaria.
e - severe forms of neutrophilic dermatoses.
III - DIGESTIVE :
a - progressive attacks of ulcerative colitis and Crohn's disease.
b - active autoimmune chronic hepatitis (with or without cirrhosis).
c - severe acute alcoholic hepatitis, histologically proven.
IV - ENDOCRINE :
a - Subacute severe De Quervain thyroiditis.
b - certain hypercalcemias.
V - HEMATOLOGICAL :
a - severe immunologic thrombocytopenic purpura.
b - autoimmune hemolytic anemias.
c - in combination with various chemotherapies in the treatment of lymphoid malignant hemopathies.
d - Acquired or congenital chronic erythroblastopenia.
VI - INFECTIOUS :
a - tuberculous pericarditis and severe forms of life-threatening tuberculosis.
b - Pneumocystis carinii pneumonia with severe hypoxia.
VII - NEOPLASICS :
a - anti-emetic treatment during antineoplastic chemotherapy.
b - oedematous and inflammatory thrust associated with antineoplastic treatments (radio and chemotherapy).
VIII - NEPHROLOGIC :
a - Nephrotic syndrome with minimal glomerular lesions.
b - Nephrotic syndrome of primitive segmental and focal hyalinosis.
c - stage III and IV of lupus nephropathy.
d - intrarenal granulomatous sarcoidosis.
e - vasculitis with renal involvement.
primitive extracapillary glomerulonephritis.
IX - NEUROLOGICAL :
a - myasthenia.
b - cerebral edema of tumoral cause.
c - chronic polyradiculoneuropathy, idiopathic, inflammatory.
d - infantile spasm (West syndrome) / Lennox-Gastaut syndrome.
e - Multiple sclerosis in relapse of intravenous corticosteroid therapy.
X - OPHTHALMOLOGIC :
severe anterior and posterior uveitis.
b - edematous exophthalmos.
c - certain optic neuropathies, in rela- tion with intravenous corticosteroids (in this indication, the first-line oral route is not recommended).
XI - ENT :
a - certain serous otitis.
b - nasosinus polyposis
c - some acute or chronic sinusitis.
d - seasonal allergic rhinitis in short cure.
Stridulous acute laryngitis (subglottic laryngitis) in children.
XII - RESPIRATORY :
a - persistent asthma, preferably in short course, in case of failure of inhaled treatment at high doses.
b - exacerbations of asthma, in particular severe acute asthma.
c - chronic obstructive bronchopneumopathy in evaluation of the reversibility of the obstructive syndrome.
d - progressive sarcoidosis.
e - diffuse pulmonary interstitial fibrosis.
XIII - RHEUMATOLOGICAL :
a - rheumatoid arthritis and some polyarthritis.
b - rhizomelic pseudopolyarthritis and Horton's disease.
c - rheumatic fever.
d - severe and rebellious cervicobrachial neuralgia.
XIV - TRANSPLANTATION OF ORGAN AND ALLOGENIC HEMATOPOIETIC STEM CELLS :
a - prophylaxis or treatment of transplant rejection.
b - prophylaxis or treatment of the graft versus host reaction.
Dosage BETAMETHASONE EG 0.05% Oral solution in drops Box of 1 Bottle with dropper 30 ml
RESERVED FOR INFANTS AND CHILDREN.
40 drops correspond to 1 ml of solution and to 0.5 mg of betamethasone.
- Anti-inflammatory equivalence (equipotence) for 5 mg prednisone: 0.75 mg betamethasone.
- The dosage should be appropriate to the condition and weight of the child.
- Attack treatment: 0.075 mg / kg / day, ie 6 drops / kg / day at 0.3 mg / kg / day of betamethasone, ie 24 drops / kg / day (0.5 to 2 mg / kg / day) equivalent prednisone).
As an indication : 150 to 600 drops for a child of 25 kg.
- Maintenance treatment: 0.03 mg / kg / day (ie 3 drops / kg / day).
As an indication : 75 drops for a child of 25 kg.
- The prescription of alternating day corticosteroid therapy (one day without corticosteroid and the second day with a double dosage of the daily dosage that would have been required) is used in children to try to limit stunting. This alternate day schedule can be considered only after control of inflammatory disease by high doses of corticosteroids, and when during decay no rebound is observed.
IN GENERAL :
- "At the attack dose" treatment should be continued until the disease is permanently controlled. Decay must be slow. Obtaining a weaning is the goal. Maintaining a maintenance dose (minimum effective dose) is a compromise that is sometimes necessary.
- For prolonged treatment at high doses, the first doses can be divided into two daily doses. Thereafter, the daily dose may be administered as a single dose preferably in the morning during the meal.
- Stop treatment :
. The rate of withdrawal depends mainly on the duration of treatment, the starting dose and the disease.
. The treatment causes resting secretions of ACTH and cortisol with sometimes lasting adrenal insufficiency. When weaning, stopping should be done gradually, in stages because of the risk of relapse: reduction of 10% every 8 to 15 days on average.
. For short courses of less than 10 days, stopping treatment does not require decay.
. When decreasing doses (prolonged cure): at the dosage of 5 to 7 mg of prednisone equivalent, when the causal disease no longer requires corticosteroid treatment, it is desirable to replace the synthetic corticoid with 20 mg / day of hydrocortisone until recovery of corticotropic function. If corticosteroid therapy is to be maintained at less than 5 mg prednisone equivalent per day, a small dose of hydrocortisone can be added to achieve a hydrocortisone equivalent of 20 to 30 mg per day. When the patient is only under hydrocortisone, it is possible to test the corticotropic axis by endocrine tests. These tests do not eliminate the possibility of adrenal insufficiency during a stress.
. Under hydrocortisone or even at a distance from arrest, the patient should be advised of the need to increase the usual dosage or to resume replacement therapy (eg 100 mg hydrocortisone intramuscularly every 6 to 8 hours) in case stress: surgery, trauma, infection.
Administration mode :
Put the drops in a little water. The ingestion of the solution is preferably done at the end of the meal.
- This medication is usually contraindicated in the following situations:
(However, there is no absolute contraindication for a corticosteroid indication of vital indication):
. Hyper-sensitivity to one of the compounds,
. Any infectious condition excluding specified indications (see indications).
. Some viruses in evolution (including hepatitis, herpes, chicken pox, shingles).
. Psychotic states still not controlled by treatment.
. Live vaccines.
- The use of this medicine is not recommended for patients with sucrose intolerance.
NOT RECOMMENDED :
This drug is generally not recommended in combination:
with non-antiarrhythmic drugs, giving torsades de pointes (see interactions).
Adverse effects Betamethasone EG
They are especially to be feared in important doses or during a prolonged treatment over several months.
- Hydro-electrolytic disorders: hypokalemia, metabolic alkalosis, water-soluble retention, arterial hypertension, congestive heart failure.
- Endocrine and metabolic disorders: iatrogenic Cushing's syndrome, inertia of ACTH secretion, sometimes permanent adrenocortical atrophy, decrease in glucose tolerance, revelation of latent diabetes, stunting of growth in children, menstrual irregularities.
- Musculoskeletal disorders: Muscular atrophy preceded by muscle weakness (increased protein catabolism), osteoporosis, pathological fractures, particularly vertebral compression, aseptic osteonecrosis of the femoral heads.
- Digestive disorders: hiccups, peptic ulcers, ulceration of the small bowel, perforations and digestive haemorrhage; acute pancreatitis has been reported, especially in children.
- Skin disorders: acne, purpura, bruising, hypertrichosis, delayed healing.
- Neuropsychic disorders:
. frequently: euphoria, insomnia, excitement;
. rarely: manic pace, confusional or confuso-oniric conditions, convulsions (general or intrathecal);
. depressive state upon discontinuation of treatment.
- Eye disorders: some forms of glaucoma and cataracts.
- Due to the presence of sorbitol, this medicine can cause digestive disorders and mild laxative effect.